Chester County News and Community Website
DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced top line results from the 14-week …
Read More
MALVERN, PA — DSG, Inc. is supporting two Phase 3 studies sponsored by Romark, L.C. to evaluate an investigational new drug for prevention of COVID-19 in elderly residents of long-term …
Read More MALVERN, PA — DSG, Inc., industry leader in eClinical software and services for life sciences, harnesses its Version 10 flagship eCaseLink™ Electronic Source System, Participant Tracker, and electronic and remote …
Read More
EXTON, PA — Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, a toll-like receptor 9 (TLR9) agonist, in combination with nivolumab, a …
Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, …
Read More
CHESTERBROOK, PA — Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System conditions, recently announced that it has initiated …
Read More
EXTON, PA — Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, reported financial results for the first quarter …
Read More
EXTON, PA — Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, announced Christine St.Clare, a member of the Company’s …
Read More
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a revenue-generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, announced it has received a second Complete Response Letter (CRL) …
Read More
MALVERN, PA — VenatoRx Pharmaceuticals, Inc., a world leader in antibacterial and antiviral drug research and development, announced that it has received $1.9 million in first-year funding from the National …
Read More